Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $501000.0.

  • Vivos Therapeutics' Change in Receivables rose 74915.25% to $501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $746000.0, marking a year-over-year increase of 23008.85%. This contributed to the annual value of $228000.0 for FY2024, which is 18941.18% up from last year.
  • Latest data reveals that Vivos Therapeutics reported Change in Receivables of $501000.0 as of Q3 2025, which was up 74915.25% from -$19000.0 recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Change in Receivables high stood at $1.8 million for Q2 2021, and its period low was -$2.6 million during Q4 2021.
  • Its 5-year average for Change in Receivables is -$12157.9, with a median of -$19000.0 in 2025.
  • In the last 5 years, Vivos Therapeutics' Change in Receivables surged by 462655.19% in 2021 and then crashed by 228333.33% in 2024.
  • Vivos Therapeutics' Change in Receivables (Quarter) stood at -$2.6 million in 2021, then skyrocketed by 84.45% to -$409000.0 in 2022, then soared by 93.64% to -$26000.0 in 2023, then rose by 7.69% to -$24000.0 in 2024, then soared by 2187.5% to $501000.0 in 2025.
  • Its last three reported values are $501000.0 in Q3 2025, -$19000.0 for Q2 2025, and $288000.0 during Q1 2025.